These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 21932114

  • 1. Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis.
    Okazaki R, Hagino H, Ito M, Sone T, Nakamura T, Mizunuma H, Fukunaga M, Shiraki M, Nishizawa Y, Ohashi Y, Matsumoto T.
    Osteoporos Int; 2012 Jun; 23(6):1737-45. PubMed ID: 21932114
    [Abstract] [Full Text] [Related]

  • 2. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.
    Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T.
    Osteoporos Int; 2009 Aug; 20(8):1429-37. PubMed ID: 19101754
    [Abstract] [Full Text] [Related]

  • 3. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
    Kumagai K, Harigane K, Kusayama Y, Tezuka T, Choe H, Inaba Y, Saito T.
    Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.
    Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
    [Abstract] [Full Text] [Related]

  • 6. Change in arterial stiffness associated with monthly bisphosphonate treatment in women with postmenopausal osteoporosis.
    Igase M, Kohara K, Tabara Y, Ohara M, Takita R, Ochi M, Okada Y, Miki T.
    Menopause; 2014 Sep; 21(9):962-6. PubMed ID: 24552979
    [Abstract] [Full Text] [Related]

  • 7. Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.
    Nakamura T, Ito M, Hashimoto J, Shinomiya K, Asao Y, Katsumata K, Hagino H, Inoue T, Nakano T, Mizunuma H, MOVEST Study Group.
    Osteoporos Int; 2015 Nov; 26(11):2685-93. PubMed ID: 26001561
    [Abstract] [Full Text] [Related]

  • 8. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC, Shi ZY, Wang B, Wu P, Kong LC, Yao JL, Li CW, Shi XL.
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [Abstract] [Full Text] [Related]

  • 9. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
    Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T.
    Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Initiation of Monthly Minodronate Therapy at an Early Stage After Hip Fracture.
    Ohishi T, Fujita T, Suzuki D, Nishida T, Okabayashi R, Yamamoto K, Ushirozako H, Banno T, Matsuyama Y.
    J Clin Densitom; 2016 Jun; 19(3):352-8. PubMed ID: 27067298
    [Abstract] [Full Text] [Related]

  • 12. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
    Ebina K, Noguchi T, Hirao M, Hashimoto J, Kaneshiro S, Yukioka M, Yoshikawa H.
    Osteoporos Int; 2016 Jan; 27(1):351-9. PubMed ID: 26475289
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of minodronate in the treatment of postmenopausal osteoporosis with low back pain: a single-centre, randomized and open-label controlled trial.
    Wang H, Huang J, Tao L, Liu D, Song C.
    Trials; 2024 Aug 13; 25(1):534. PubMed ID: 39135126
    [Abstract] [Full Text] [Related]

  • 14. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
    Cosman F, Gilchrist N, McClung M, Foldes J, de Villiers T, Santora A, Leung A, Samanta S, Heyden N, McGinnis JP, Rosenberg E, Denker AE.
    Osteoporos Int; 2016 Jan 13; 27(1):377-86. PubMed ID: 26556736
    [Abstract] [Full Text] [Related]

  • 15. Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
    Hagino H, Kishimoto H, Ohishi H, Horii S, Nakamura T.
    Bone; 2014 Feb 13; 59():44-52. PubMed ID: 24184313
    [Abstract] [Full Text] [Related]

  • 16. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.
    Soen S, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Ito M, Nakano T, Hagino H, Hirakawa A, Matsumoto T.
    J Bone Miner Metab; 2020 Jul 13; 38(4):511-521. PubMed ID: 31970477
    [Abstract] [Full Text] [Related]

  • 17. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
    Nakatoh S.
    J Bone Miner Metab; 2018 Mar 13; 36(2):221-228. PubMed ID: 28293779
    [Abstract] [Full Text] [Related]

  • 18. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH, Ensrud KE, Burdeska A, Mills T, Oral Ibandronate Study Group.
    J Bone Miner Res; 2004 Jan 13; 19(1):11-8. PubMed ID: 14753731
    [Abstract] [Full Text] [Related]

  • 19. Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study.
    Sakai A, Ikeda S, Okimoto N, Matsumoto H, Teshima K, Okazaki Y, Fukuda F, Arita S, Tsurukami H, Nagashima M, Yoshioka T.
    Osteoporos Int; 2014 Sep 13; 25(9):2245-53. PubMed ID: 24899103
    [Abstract] [Full Text] [Related]

  • 20. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar 13; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.